Please assess the completion status of the following clinical trial:

Trial Title: Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic carcinoma of the breast that is progressive~* Premenopausal, defined as any of:~  1. Last menstrual period within 3 months, or~ 2. Post-hysterectomy without bilateral oophorectomy and with follicle-stimulating hormone (FSH) in the premenopausal range, or,~ 3. If tamoxifen administered within the past 3 months, plasma estradiol must be in the premenopausal range~* Either positive estrogen and/or progesterone receptor determination by Immunohistochemistry (IHC) or competitive binding assay on metastatic disease, or if not performed on their metastatic disease a positive result on their primary breast cancer specimen.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~* Granulocytes \> 1500/mm\^3~* Platelets \> 100,000/mm\^3~* Serum glutamic oxaloacetic transaminase (SGOT) \< 2.5 x upper limit of normal~* Total bilirubin \< 1.5 mg/dL~* May have received irradiation to bony sites of disease for pain control or for prevention of fracture. The irradiated site(s) will NOT be evaluable for disease response.~* Must be using effective contraception or not be of childbearing potential~* Signed written informed consent~INCLUSION CRITERIA~* Active, unresolved infection~* Active malignancy other than breast cancer, in situ carcinoma of the cervix, or non-melanomatous skin cancers in the past 5 years~* Prior treatment with an aromatase inhibitor or inactivator~* Prior treatment with an luteinizing hormone-releasing hormone (LH/RH) agonist/antagonist~* Adjuvant chemotherapy within 6 months of study entry.~* Received chemotherapy or hormonal therapy in the 3 weeks prior to enrollment~* Central nervous system metastasis~* Lymphangitic pulmonary metastasis~* Pregnant or lactating

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Anastrozole + Goserelin (Type: EXPERIMENTAL): Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily. No dose attenuation or escalation was allowed for either goserelin or anastrozole.

Based on this trial design, predict the completion outcome and termination type (if applicable).